Iberdomide vs Mezigdomide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Iberdomide · Zenbexus

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomasmall molecule (CELMoD / cereblon E3 ligase modulator)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT05560399 (registry estimate)

No aligned efficacy figure on record for this race.

Mezigdomide

Developed by Bristol-Myers Squibb

Phase 3 in Multiple Myelomasmall molecule
Partial signal

NCT05552976 · Phase 3 · active, not recruiting

This was a randomized, open-label Phase 3 trial with 606 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-03-09. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.

Next expected readout: November 2026 · NCT03989414 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Up to approximately 5 years): Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09). (met)

Result source: NCT05552976

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIberdomideMezigdomide
PFS, median—Trial running · NCT04934475—Trial running · NCT05552976
OS, median—Trial running · NCT04934475—Trial running · NCT05552976
ORR—Trial running · NCT04934475—Trial running · NCT05552976
VGPR or better—Trial running · NCT04934475—Trial running · NCT05552976
MRD negativity—Trial running · NCT04934475—Trial running · NCT05552976

PFS, median

Iberdomide
—Trial running · NCT04934475
Mezigdomide
—Trial running · NCT05552976

OS, median

Iberdomide
—Trial running · NCT04934475
Mezigdomide
—Trial running · NCT05552976

ORR

Iberdomide
—Trial running · NCT04934475
Mezigdomide
—Trial running · NCT05552976

VGPR or better

Iberdomide
—Trial running · NCT04934475
Mezigdomide
—Trial running · NCT05552976

MRD negativity

Iberdomide
—Trial running · NCT04934475
Mezigdomide
—Trial running · NCT05552976
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Iberdomide: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mezigdomide
Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09). NCT05552976 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iberdomide's landscape · Mezigdomide's landscape